AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more. Amerisourcebergen.com.

Dark Horse Consulting Group is a specialist consulting firm that operates exclusively in the cell and gene therapy space. With our roots in CMC, today cover all areas of CGT product development, including regulatory affairs, manufacturing, process development, preclinical development, analytics, quality, project/program management, device development, quantitative modelling, facilities design & engineering, and investment support (e.g., diligence & strategic consulting). Our consultants have a wide range of experiences from backgrounds in the CGT industry or from senior roles in FDA, enabling us to offer a breadth of technical subject matter and regulatory expertise to each client.

ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. 

Despite the explosive innovation in therapeutic discovery and development, biomanufacturing innovation and platforms have not kept pace. We intend to change that.

Resilience is a first-of-kind technology-based manufacturing company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains from disruption. Founded in 2020, the Company is building a network of high-tech biomanufacturing platforms and capacity to ensure the medicines of today and tomorrow can be made at the quality, cost, and scale to meet patient needs. Resilience offers solutions for cell and gene therapy services from early clinical through commercial manufacturing including: process and analytical development, cell banking, viral vector production (AAV, LVV, and other viral vectors, immunotherapies, HSCs, iPSCs, and regenerative medicines). We are continuously advancing the science and technology of CGT biomanufacturing by investing heavily in R&D, manufacturing platforms and infrastructure. We focus on deep-rooted partnerships and novel business models. Resilience aims to free its partners’ time and resources to focus on therapeutic discoveries that improve patients’ lives and democratize access to medicines.

For more information, visit www.Resilience.com.

WuXi Advanced Therapies is a global Contract Testing Development and Manufacturing Organisation (CTDMO) headquartered in Philadelphia, USA,

in the heart of the cell and gene therapy industry. It is the advanced therapies business unit of WuXi AppTec and provides innovative technology platforms for lentiviral and AAV plasmid, viral vector and cell therapy manufacture and testing, accelerating time to market for cell and gene therapies.

We are a comprehensive provider of viral vector and cell therapy testing for the advanced therapy industry, conducting testing for both therapeutics developers

and other CDMOs. With OXGENE as our UK-based discovery engine, our in-house testing capabilities and significant manufacturing expertise combine to provide a fully integrated end-to-end solution for cell and gene therapy research, development, testing and GMP manufacture that delivers a critical competitive advantage to our customers as we work together to cure faster and cure more.

Invetech helps cell and gene therapy developers to visualize, strategize and manage the future. With proven processes, expert insights and full-spectrum services, we swiftly accelerate life-changing therapies from clinical to commercial-scale manufacturing. With configurable technology platforms and automated production systems, we enable predictable, reproducible products of the highest quality and efficacy. Our integrated approach brings together biological scientists, engineers, designers and program managers to deliver successful market offerings to more people globally. Working in close collaboration with early-stage and mature life science companies, we are committed to advancing the next generation of vital, emerging therapies to revolutionize healthcare and precision medicine.

TrakCel is the first provider of integrated cellular orchestration solutions for the precise management, control and tracking of cell and gene therapy products. With the largest number of live deployments supporting the broadest number of therapy classes in industry, TrakCel has built a deep understanding of the unique challenges faced by advanced therapy developers globally.

Our goal is to provide cell and gene therapy software solutions that offer visibility, insight and scalability to streamline the delivery of therapies to patients at their most vulnerable.

Our mission is to support improved patient safety and care through innovative electronic solutions designed to streamline data management and improve quality. Since 2001, we have designed, developed and delivered technology that enables our customers to deliver life-saving products and services while gaining efficiencies, ensuring compliance and improving patient safety.

Cryoport and BioLife Cellular Therapy Services, part of the global biopharma company, Takeda Pharmaceutical Company, have joined forces in a strategic relationship to establish an integrated supply chain platform to offer standardized cell therapy collection, processing, storage, and distribution services. The platform will provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies. The relationship aims to shorten processing & logistics time and standardize collections to accelerate cell therapy programs.

Corning offers a range of innovative solutions for efficient scale-up of adherent and suspension cell cultures for cell and gene therapy research and production. Whether your goal is stem cell expansion or viral vector production, our platforms, including HYPERStack® vessels, the high-yield Ascent® FBR™ system, our suspension seed train solutions including our new Rocking Bioreactor, polystyrene and dissolvable microcarriers, and closed system solutions can help get you there. Choose from hundreds of vessels, the widest selection of cell culture surfaces, and custom media in a variety of single-use technology configurations.